2024 Q3 Form 10-Q Financial Statement
#000117867024000041 Filed on August 01, 2024
Income Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| Revenue | $500.9M | $659.8M |
| YoY Change | -33.26% | 107.0% |
| Cost Of Revenue | $81.98M | $67.27M |
| YoY Change | 3.15% | -21.2% |
| Gross Profit | $418.9M | $592.6M |
| YoY Change | -37.57% | 153.9% |
| Gross Profit Margin | 83.63% | 89.8% |
| Selling, General & Admin | $221.0M | $248.4M |
| YoY Change | 10.95% | 15.7% |
| % of Gross Profit | 52.75% | 41.92% |
| Research & Development | $270.9M | $294.1M |
| YoY Change | 7.01% | 18.35% |
| % of Gross Profit | 64.67% | 49.64% |
| Depreciation & Amortization | $13.98M | $15.00M |
| YoY Change | 4.34% | 13.84% |
| % of Gross Profit | 3.34% | 2.53% |
| Operating Expenses | $491.9M | $542.5M |
| YoY Change | 8.75% | 17.12% |
| Operating Profit | -$76.91M | $48.61M |
| YoY Change | -135.96% | -121.15% |
| Interest Expense | -$40.07M | -$61.09M |
| YoY Change | -229.7% | 61.71% |
| % of Operating Profit | -125.65% | |
| Other Income/Expense, Net | -$31.76M | -$59.78M |
| YoY Change | -49.69% | 805.36% |
| Pretax Income | -$108.7M | -$11.17M |
| YoY Change | -172.09% | -95.93% |
| Income Tax | $2.907M | $5.722M |
| % Of Pretax Income | ||
| Net Earnings | -$111.6M | -$16.89M |
| YoY Change | -175.51% | -93.88% |
| Net Earnings / Revenue | -22.27% | -2.56% |
| Basic Earnings Per Share | -$0.87 | -$0.13 |
| Diluted Earnings Per Share | -$0.87 | -$0.13 |
| COMMON SHARES | ||
| Basic Shares Outstanding | 128.4M shares | 126.5M shares |
| Diluted Shares Outstanding | 128.6M shares | 126.7M shares |
Balance Sheet
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $2.772B | $2.615B |
| YoY Change | 15.7% | 27.08% |
| Cash & Equivalents | $1.100B | $968.5M |
| Short-Term Investments | $1.672B | $1.646B |
| Other Short-Term Assets | $145.4M | $154.7M |
| YoY Change | -8.01% | 6.39% |
| Inventory | $75.99M | $83.98M |
| Prepaid Expenses | ||
| Receivables | $353.9M | $309.5M |
| Other Receivables | $64.58M | $288.2M |
| Total Short-Term Assets | $3.355B | $3.173B |
| YoY Change | 12.39% | 25.71% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $507.0M | $517.2M |
| YoY Change | -3.54% | -29.76% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | ||
| YoY Change | ||
| Other Assets | $77.62M | $71.93M |
| YoY Change | 3.28% | -49.37% |
| Total Long-Term Assets | $849.6M | $836.8M |
| YoY Change | -0.47% | -4.73% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $3.355B | $3.173B |
| Total Long-Term Assets | $849.6M | $836.8M |
| Total Assets | $4.205B | $4.010B |
| YoY Change | 9.53% | 17.85% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $70.81M | $73.98M |
| YoY Change | -4.11% | 23.82% |
| Accrued Expenses | $946.2M | $808.6M |
| YoY Change | 32.68% | 26.23% |
| Deferred Revenue | $71.03M | $69.01M |
| YoY Change | -7.92% | 26.3% |
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $1.221B | $1.055B |
| YoY Change | 28.52% | 33.81% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $1.024B | $1.023B |
| YoY Change | 0.38% | 0.38% |
| Other Long-Term Liabilities | $357.5M | $350.4M |
| YoY Change | 27.34% | -82.51% |
| Total Long-Term Liabilities | $357.5M | $350.4M |
| YoY Change | 27.34% | -88.4% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $1.221B | $1.055B |
| Total Long-Term Liabilities | $357.5M | $350.4M |
| Total Liabilities | $4.173B | $4.013B |
| YoY Change | 4.19% | 5.31% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | -$7.204B | -$7.092B |
| YoY Change | 4.84% | 1.04% |
| Common Stock | $7.261B | $7.124B |
| YoY Change | 7.76% | 7.15% |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $32.35M | -$3.067M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $4.205B | $4.010B |
| YoY Change | 9.53% | 17.85% |
Cashflow Statement
| Concept | 2024 Q3 | 2024 Q2 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$111.6M | -$16.89M |
| YoY Change | -175.51% | -93.88% |
| Depreciation, Depletion And Amortization | $13.98M | $15.00M |
| YoY Change | 4.34% | 13.84% |
| Cash From Operating Activities | $43.71M | $124.2M |
| YoY Change | -87.84% | -310.49% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $4.192M | $8.018M |
| YoY Change | -75.49% | -49.63% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | -$26.06M | $41.96M |
| YoY Change | -513.62% | 482.26% |
| Cash From Investing Activities | -$30.25M | $33.94M |
| YoY Change | 180.09% | -489.53% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | ||
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 102.8M | 131.5M |
| YoY Change | 210.44% | 146.27% |
| NET CHANGE | ||
| Cash From Operating Activities | 43.71M | 124.2M |
| Cash From Investing Activities | -30.25M | 33.94M |
| Cash From Financing Activities | 102.8M | 131.5M |
| Net Change In Cash | 116.2M | 289.6M |
| YoY Change | -69.56% | -2124.43% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | $43.71M | $124.2M |
| Capital Expenditures | $4.192M | $8.018M |
| Free Cash Flow | $39.51M | $116.1M |
| YoY Change | -88.46% | -255.05% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.13 | |
| CY2024Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
126733000 | shares |
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
126435000 | shares | |
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
158637000 | usd | |
| us-gaap |
Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
|
1770000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
160407000 | usd | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
-13061000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
156309000 | usd | |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
814884000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
868556000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
971193000 | usd |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
39101000 | usd | |
| CY2024Q2 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
128021000 | shares |
| CY2024Q2 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
128021000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
125794000 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
125794000 | shares |
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.66 | ||
| us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-3.62 | ||
| us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
124387000 | shares | |
| CY2024Q2 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q2 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-2.21 | |
| CY2023Q2 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
124659000 | shares |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-158223000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
26418000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
41136000 | usd |
| CY2023Q1 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
5530000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-174101000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-259240000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
38115000 | usd |
| CY2023Q2 | us-gaap |
Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
|
9984000 | usd |
| CY2023Q2 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
76990000 | usd |
| CY2023Q2 | us-gaap |
Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
|
2044000 | usd |
| CY2023Q2 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-276024000 | usd |
| CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-408131000 | usd |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-82824000 | usd | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-450125000 | usd | |
| us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
28520000 | usd | |
| us-gaap |
Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
|
27244000 | usd | |
| alny |
Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
|
21658000 | usd | |
| alny |
Amortization And Interest Accretion Related To Operating Leases
AmortizationAndInterestAccretionRelatedToOperatingLeases
|
22282000 | usd | |
| alny |
Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
|
61103000 | usd | |
| alny |
Non Cash Interest Expense On Sale Of Future Royalties
NonCashInterestExpenseOnSaleOfFutureRoyalties
|
51647000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
134635000 | usd | |
| us-gaap |
Share Based Compensation
ShareBasedCompensation
|
115749000 | usd | |
| us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
-1289000 | usd | |
| us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
-867000 | usd | |
| alny |
Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
|
-64228000 | usd | |
| alny |
Change In Fair Value Of Liability Obligation
ChangeInFairValueOfLiabilityObligation
|
-36686000 | usd | |
| us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
-15365000 | usd | |
| us-gaap |
Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
|
-8252000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-10050000 | usd | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-16183000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-6816000 | usd | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-1582000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
13775000 | usd | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
29109000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
69605000 | usd | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
766000 | usd | |
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-23791000 | usd | |
| us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-23847000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-219506000 | usd | |
| us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
12866000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
42643000 | usd | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-225461000 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
20991000 | usd | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
29810000 | usd | |
| us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
717826000 | usd | |
| us-gaap |
Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
|
812887000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
705137000 | usd | |
| us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
757767000 | usd | |
| us-gaap |
Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
|
57875000 | usd | |
| us-gaap |
Proceeds From Sale Of Restricted Investments
ProceedsFromSaleOfRestrictedInvestments
|
58475000 | usd | |
| us-gaap |
Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
|
57875000 | usd | |
| us-gaap |
Payments To Acquire Restricted Investments
PaymentsToAcquireRestrictedInvestments
|
58475000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-33680000 | usd | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-84930000 | usd | |
| us-gaap |
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
|
91765000 | usd | |
| us-gaap |
Proceeds From Derivative Instrument Financing Activities
ProceedsFromDerivativeInstrumentFinancingActivities
|
8000000 | usd | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
99765000 | usd | |
| us-gaap |
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
2046000 | usd | |
| us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-208580000 | usd | |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
659976000 | usd |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
17128000 | usd | |
| us-gaap |
Nature Of Operations
NatureOfOperations
|
NATURE OF BUSINESS<div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) commenced operations on June 14, 2002 as a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on ribonucleic acid interference, or RNAi. We are committed to the advancement of our company strategy of building a multi-product, global, commercial biopharmaceutical company with a deep and sustainable clinical pipeline of RNAi therapeutics for future growth and a robust, organic research engine for sustainable innovation and great potential for patient impact. Since inception, we have focused on discovering, developing and commercializing RNAi therapeutics by establishing and maintaining a strong intellectual property position in the RNAi field, establishing strategic collaborations with leading pharmaceutical and life sciences companies, generating revenues through licensing agreements, and ultimately developing and commercializing RNAi therapeutics globally, either independently or with our strategic collaborators. We have devoted substantially all of our efforts to business planning, research, development, manufacturing and commercial efforts, acquiring, filing and expanding intellectual property rights, recruiting management and technical staff, and raising capital. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In early 2021, we launched our </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">strategy, which focuses on our planned transition to a top-tier biotech company by the end of 2025. With </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Alnylam P</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">x25</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, we aim to deliver transformative rare and prevalent disease medicines for patients around the world through sustainable innovation, while delivering exceptional financial performance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of June 30, 2024, we have five marketed products, including one product commercialized by a collaborator, and multiple late-stage investigational programs advancing towards potential commercialization. We currently generate worldwide product revenues from four commercialized products, ONPATTRO, AMVUTTRA, GIVLAARI and OXLUMO, primarily in the United States, or U.S., and Europe.</span></div> | ||
| CY2024Q2 | alny |
Number Of Marketed Products
NumberOfMarketedProducts
|
5 | product |
| CY2024Q2 | alny |
Number Of Partnered Products
NumberOfPartneredProducts
|
1 | product |
| CY2024Q2 | alny |
Number Of Commercialized Products
NumberOfCommercializedProducts
|
4 | product |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. In our condensed consolidated financial statements, we use estimates and assumptions related to our inventory valuation and related reserves, liability related to the sale of future royalties, development derivative liability, income taxes, deferred tax asset valuation allowances, revenue recognition, research and development expenses, and stock-based compensation. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> | ||
| CY2024Q2 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
200000000.0 | usd |
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
228700000 | usd | |
| CY2023Q2 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
4800000 | usd |
| us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
10300000 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
|
0 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
0 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
|
0 | usd | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
|
0 | usd | |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
1691630000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
181000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2928000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1688883000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
1648127000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
3030000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1482000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1649675000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
1646268000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
|
1615516000 | usd |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
42615000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
|
34159000 | usd |
| CY2024Q2 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1688883000 | usd |
| CY2023Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
1649675000 | usd |
| CY2024Q2 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
26021000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials
InventoryRawMaterials
|
23346000 | usd |
| CY2024Q2 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
66535000 | usd |
| CY2023Q4 | us-gaap |
Inventory Work In Process
InventoryWorkInProcess
|
76963000 | usd |
| CY2024Q2 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
27855000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods
InventoryFinishedGoods
|
25123000 | usd |
| CY2024Q2 | alny |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
120411000 | usd |
| CY2023Q4 | alny |
Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
|
125432000 | usd |
| CY2024Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
968492000 | usd |
| CY2023Q2 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
657800000 | usd |
| CY2024Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
2701000 | usd |
| CY2023Q2 | us-gaap |
Restricted Cash
RestrictedCash
|
2176000 | usd |
| CY2024Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
971193000 | usd |
| CY2023Q2 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
|
659976000 | usd |
| us-gaap |
Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
|
-7034000 | usd | |
| us-gaap |
Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
|
4228000 | usd | |
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
-11262000 | usd | |
| us-gaap |
Oci Before Reclassifications Net Of Tax Attributable To Parent
OciBeforeReclassificationsNetOfTaxAttributableToParent
|
5472000 | usd | |
| us-gaap |
Reclassification From Aoci Current Period Net Of Tax Attributable To Parent
ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
|
-2102000 | usd | |
| us-gaap |
Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
|
7574000 | usd | |
| CY2024Q2 | us-gaap |
Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
|
0.11 | |
| CY2024Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
89288000 | usd |
| CY2023Q2 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
75802000 | usd |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
134635000 | usd | |
| us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
115749000 | usd | |
| CY2024Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
808000 | usd |
| CY2023Q2 | us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
1188000 | usd |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
1616000 | usd | |
| us-gaap |
Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
|
2377000 | usd | |
| CY2024Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
90096000 | usd |
| CY2023Q2 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
76990000 | usd |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
136251000 | usd | |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
118126000 | usd | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
12721000 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13942000 | shares | |
| CY2022Q3 | alny |
Number Of Patents
NumberOfPatents
|
2 | patent |
| CY2022Q3 | alny |
Number Of Lawsuits
NumberOfLawsuits
|
1 | lawsuit |
| CY2023Q3 | alny |
Number Of Disputed Terms In Lawsuit
NumberOfDisputedTermsInLawsuit
|
3 | disputed_term |
| CY2023Q3 | alny |
Number Of Disputed Terms In Lawsuit Construed
NumberOfDisputedTermsInLawsuitConstrued
|
2 | disputed_term |
| CY2023Q3 | alny |
Number Of Disputed Terms In Lawsuit
NumberOfDisputedTermsInLawsuit
|
3 | disputed_term |
| CY2023Q3 | us-gaap |
Gain Contingency Patents Found Not Infringed Upon Number
GainContingencyPatentsFoundNotInfringedUponNumber
|
2 | patent |
| CY2023Q2 | alny |
Number Of Patents
NumberOfPatents
|
1 | patent |
| CY2023Q4 | alny |
Number Of Lawsuits
NumberOfLawsuits
|
2 | lawsuit |
| CY2023Q3 | alny |
Number Of Cases
NumberOfCases
|
1 | case |
| CY2024Q2 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q2 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false |
